BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35242698)

  • 41. Exploring the sonodynamic effects of bacteriochlorophyll a.
    Jia L; Wang L; Song Y; Pang X; Zhao J
    Front Bioeng Biotechnol; 2023; 11():1186897. PubMed ID: 37251570
    [No Abstract]   [Full Text] [Related]  

  • 42. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
    Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
    Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Noninvasive quantification of target availability during therapy using paired-agent fluorescence tomography.
    Meng B; Folaron MR; Strawbridge RR; Sadeghipour N; Samkoe KS; Tichauer K; Davis SC
    Theranostics; 2020; 10(24):11230-11243. PubMed ID: 33042280
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IR780-based diffuse fluorescence tomography for cancer detection.
    He Z; Zhang L; Xing L; Sun W; Gao X; Zhang Y; Gao F
    J Biophotonics; 2024 May; 17(5):e202300493. PubMed ID: 38329194
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells.
    Kol A; Terwisscha van Scheltinga A; Pool M; Gerdes C; de Vries E; de Jong S
    Oncotarget; 2017 Jul; 8(28):45432-45446. PubMed ID: 28467975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High levels of EGFR prevent sulforaphane-induced reactive oxygen species-mediated apoptosis in non-small-cell lung cancer cells.
    Wang TH; Chen CC; Huang KY; Shih YM; Chen CY
    Phytomedicine; 2019 Nov; 64():152926. PubMed ID: 31454652
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Theranostic Nanoplatform with Sequential SDT and ADV Effects in Response to Well-Programmed LIFU Irradiation for Cervical Cancer.
    Zhou J; Hou J; Liu S; Xu J; Luo Y; Zheng J; Li X; Wang Z; Ran H; Guo D
    Int J Nanomedicine; 2021; 16():7995-8012. PubMed ID: 34916791
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IR780-loaded folate-targeted nanoparticles for near-infrared fluorescence image-guided surgery and photothermal therapy in ovarian cancer.
    Song J; Zhang N; Zhang L; Yi H; Liu Y; Li Y; Li X; Wu M; Hao L; Yang Z; Wang Z
    Int J Nanomedicine; 2019; 14():2757-2772. PubMed ID: 31118609
    [No Abstract]   [Full Text] [Related]  

  • 51. Near infrared fluorescent imaging of brain tumor with IR780 dye incorporated phospholipid nanoparticles.
    Li S; Johnson J; Peck A; Xie Q
    J Transl Med; 2017 Jan; 15(1):18. PubMed ID: 28114956
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-EGFR Peptide-Conjugated Triangular Gold Nanoplates for Computed Tomography/Photoacoustic Imaging-Guided Photothermal Therapy of Non-Small Cell Lung Cancer.
    Zhao Y; Liu W; Tian Y; Yang Z; Wang X; Zhang Y; Tang Y; Zhao S; Wang C; Liu Y; Sun J; Teng Z; Wang S; Lu G
    ACS Appl Mater Interfaces; 2018 May; 10(20):16992-17003. PubMed ID: 29722264
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer.
    Xiao W; Ma W; Wei S; Li Q; Liu R; Carney RP; Yang K; Lee J; Nyugen A; Yoneda KY; Lam KS; Li T
    J Hematol Oncol; 2019 Jun; 12(1):56. PubMed ID: 31182116
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
    Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
    Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling.
    Wang W; Xia X; Chen K; Chen M; Meng Y; Lv D; Yang H
    Front Oncol; 2021; 11():665045. PubMed ID: 34168988
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Affibody-Modified Gd@C-Dots with Efficient Renal Clearance for Enhanced MRI of EGFR Expression in Non-Small-Cell Lung Cancer.
    Wu Y; Li H; Yan Y; Wang K; Cheng Y; Li Y; Zhu X; Xie J; Sun X
    Int J Nanomedicine; 2020; 15():4691-4703. PubMed ID: 32636625
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
    Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
    Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.